Qualitative ctDNA analysis showed that presence of KRAS mutations in ctDNA could predict the effectiveness of targeted therapies, illustrated by an absence of clinical response to anti-EGFR therapy in stage IV CRC patients with KRAS mutations detected in pretherapeutic blood samples (61). This evidence concerns the gene KRAS and colorectal carcinoma.